edaravone has been researched along with Cytokine Release Syndrome in 1 studies
Cytokine Release Syndrome: A severe immune reaction characterized by excessive release of CYTOKINES. Symptoms include DYSPNEA; FEVER; HEADACHE; HYPOTENSION; NAUSEA; RASH; TACHYCARDIA; HYPOXIA; HYPERFERRITINEMIA, and MULTIPLE ORGAN FAILURE. It is associated with viral infections, SEPSIS; AUTOIMMUNE DISEASES and a variety of factors used in IMMUNOTHERAPY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cytokine storm is the most prominent hallmark in patients with coronavirus disease 2019 (COVID-19) that stimulates the free radical storm, both of which induce an overactive immune response during viral infection." | 3.11 | Evaluating the effect of Edaravone on clinical outcome of patients with severe COVID-19 admitted to ICU: a randomized clinical trial. ( Ardalan, M; Haramshahi, M; Hejazian, SM; Javanali, F; Mirghaffari, A; Moslemi, M; Sadeghi, A; Shaddelan, M; Sharifi, A; Valizadeh, H; Zununi Vahed, S, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moslemi, M | 1 |
| Hejazian, SM | 1 |
| Shaddelan, M | 1 |
| Javanali, F | 1 |
| Mirghaffari, A | 1 |
| Sadeghi, A | 1 |
| Valizadeh, H | 1 |
| Sharifi, A | 1 |
| Haramshahi, M | 1 |
| Ardalan, M | 1 |
| Zununi Vahed, S | 1 |
1 trial available for edaravone and Cytokine Release Syndrome
| Article | Year |
|---|---|
Evaluating the effect of Edaravone on clinical outcome of patients with severe COVID-19 admitted to ICU: a randomized clinical trial.
Topics: COVID-19 Drug Treatment; Cytokine Release Syndrome; Edaravone; Humans; Intensive Care Units; SARS-Co | 2022 |